Identification of a clade A HIV envelope immunogen from Protocol G that elicits neutralizing antibodies to tier 2 viruses

Identification of a clade A HIV envelope immunogen from Protocol G that elicits neutralizing antibodies to tier 2 viruses

Bibliographic Details
Main Authors:	Hoffenberg S, Pond S, Carpov A, Wagner D, Wilson A, Powell R, Lindsay R, Arendt H, DeStefano J, Poignard P, Simek M, Fling S, Phogat S, Labranche C, Montefiori D, Burton D, Parks C, King C, Koff W, Caulfield M
Format:	Article
Language:	English
Published:	BMC 2012-09-01
Series:	Retrovirology

Similar Items

Inverse dose-response to gp140 YU2 foldon trimer formulated with aluminum phosphate and ISCOMATRIX® adjuvants
by: Wilson A, et al.
Published: (2012-09-01)

Priming with DNA encoding functional trimers and boosting with soluble trimeric protein elicited tier 2 neutralizing antibodies in non-human primates
by: Chakrabarti BK, et al.
Published: (2012-09-01)

HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site.
by: Nathanael P McCurley, et al.
Published: (2017-01-01)

Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies.
by: Douglas H Smith, et al.
Published: (2010-08-01)

Thermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies.
by: Yu Feng, et al.
Published: (2016-08-01)

S021-06 OA. Potent and broad neutralizing antibodies from HIV-1 non-clade B infected donor reveal a new HIV-1 vaccine target
by: Kaminsky S, et al.
Published: (2009-10-01)

Identification of Non-HIV Immunogens That Bind to Germline b12 Predecessors and Prime for Elicitation of Cross-clade Neutralizing HIV-1 Antibodies.
by: Zheng Yang, et al.
Published: (2015-01-01)

Viral vector delivery of Env trimer immunogens
by: Parks CL, et al.
Published: (2012-09-01)

Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein.
by: Russell Vassell, et al.
Published: (2015-01-01)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
by: Han D, et al.
Published: (2012-09-01)

P05-12. A computationally designed immunogen elicits potent anti-V3 neutralizing antibodies
by: Stamatatos L, et al.
Published: (2009-10-01)

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
by: Richard Stebbings, et al.
Published: (2012-01-01)

Immunogenicity of the outer domain of a HIV-1 clade C gp120
by: Xu Xiaodong, et al.
Published: (2007-05-01)

R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.
by: Nagadenahalli B Siddappa, et al.
Published: (2010-07-01)

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.
by: Ema T Crooks, et al.
Published: (2015-05-01)

Lay conceptions of personality : eliciting tiers of a scientific conception of personality
by: Krahé, Barbara, et al.
Published: (1987)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
by: Spearman P, et al.
Published: (2012-09-01)

Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.
by: Yvonne Rosenberg, et al.
Published: (2015-01-01)

Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector.
by: Sunil K Khattar, et al.
Published: (2013-01-01)

Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization
by: Turner, Hannah L., et al.
Published: (2021)

Comparison of immunogenicity elicited by two prime-boost strategies against tuberculosis
by: M. Lu, et al.
Published: (2014-04-01)

An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV.
by: Jennifer D Watkins, et al.
Published: (2011-03-01)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
by: Sunil K. Khattar, et al.
Published: (2014-01-01)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector.
by: Sunil K. Khattar, et al.
Published: (2014-01-01)

Development of chimeric HIV Env immunogens for mucosal delivery with attenuated canine distemper virus (CDV) vaccine vectors
by: Zhang X, et al.
Published: (2012-09-01)

Rationally designed HIV envelope glycoproteins delivered in a novel adjuvant elicited more broadly reactive antigen-specific antibody responses
by: Dey AK, et al.
Published: (2012-09-01)

A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies
by: Rita Calado, et al.
Published: (2020-04-01)

Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques.
by: Emma J Bowles, et al.
Published: (2014-01-01)

Safety, immunogenicity and duration of immunity elicited by an inactivated bovine ephemeral fever vaccine.
by: Orly Aziz-Boaron, et al.
Published: (2013-01-01)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
by: Mata-Fink, Jordi, et al.
Published: (2013)

P19-14. Recombinant alphavirus replicon particles as a platform to evaluate immunogenicity of early transmitted clade C virus envelopes
by: Srivastava I, et al.
Published: (2009-10-01)

Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.
by: Sandhya Vasan, et al.
Published: (2010-01-01)

P19-42. Engineering, expression and antigenic and immunogenic characterization of novel soluble clade A/B heterotrimeric gp140-envelope glycoproteins
by: Stamatatos L, et al.
Published: (2009-10-01)

Allotransplanted neurons used to repair peripheral nerve injury do not elicit overt immunogenicity.
by: Weimin Liu, et al.
Published: (2012-01-01)

Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine
by: De Groot AS, et al.
Published: (2012-09-01)

Broad antibody mediated cross-neutralization and preclinical immunogenicity of new codon-optimized HIV-1 clade CRF02_AG and G primary isolates.
by: Simon M Agwale, et al.
Published: (2011-01-01)

P17-12. Immunogenicity comparison of dna vaccines encompassing HIV-1 tat, rev, integrase (C-half), vif and nef genes derived from different clades
by: Yuan S, et al.
Published: (2009-10-01)

Development of a HIV-1 vaccine using an orally-administered, replication-competent adenovirus serotype 4 vector expressing Env clade C glycoprotein
by: Alexander J, et al.
Published: (2012-09-01)

Hyperglycosylated resurfaced stabilized GP120 core as an immunogen elicits antibodies targeted at the CD4-binding site
by: Dai K, et al.
Published: (2012-09-01)

Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates.
by: Joseph R Francica, et al.
Published: (2019-06-01)